IV Antibiotic Selection for Pneumonia

Introduction to Antibiotic Selection

The American Thoracic Society and the Infectious Diseases Society of America recommend starting with piperacillin-tazobactam 4.5g IV every 6 hours as the backbone regimen for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), adding vancomycin or linezolid for MRSA coverage and a second antipseudomonal agent based on mortality risk factors and local resistance patterns 1, 2

The choice of IV antibiotics depends critically on two factors: mortality risk and MRSA risk factors, as stated by the Infectious Diseases Society of America 2
High mortality risk factors include need for ventilatory support due to pneumonia, septic shock at time of presentation, ARDS preceding VAP, and acute renal replacement therapy prior to VAP onset 1, 2, 3
MRSA risk factors include prior IV antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin-resistant, unknown MRSA prevalence, and five or more days of hospitalization prior to VAP 1, 2

For ventilator-associated pneumonia (VAP), triple therapy is standard, choosing one agent from each category: MRSA coverage, primary antipseudomonal β-lactam, and second antipseudomonal agent, as recommended by the Infectious Diseases Society of America 1
Vancomycin 15 mg/kg IV q8-12h or linezolid 600 mg IV q12h can be used for MRSA coverage 1, 2
Piperacillin-tazobactam 4.5g IV q6h is the preferred first-line agent for primary antipseudomonal β-lactam coverage 1
A second antipseudomonal agent such as ciprofloxacin 400 mg IV q8h or amikacin 15-20 mg/kg IV q24h can be added based on mortality risk factors and local resistance patterns 1

All IV antibiotics should be infused over 30 minutes to optimize pharmacokinetics and minimize adverse effects, as recommended by the Infectious Diseases Society of America 1

Aztreonam should not be used as monotherapy due to its lack of gram-positive activity, and requires addition of MRSA coverage, as stated by the Infectious Diseases Society of America 2, 3
Aminoglycoside monotherapy should be avoided due to lower clinical response rates compared to other regimens, as reported by the Infectious Diseases Society of America 1
Polymyxins should be reserved for settings with high multidrug resistance prevalence and local expertise, not for routine empiric therapy, as recommended by the Infectious Diseases Society of America 1

Once culture results return, narrow antibiotic spectrum based on susceptibilities to reduce C. difficile risk, adverse effects, and resistance development, as recommended by the Infectious Diseases Society of America 1
If MRSA was covered empirically but not isolated, discontinue vancomycin or linezolid, as stated by the Infectious Diseases Society of America 2